세계 혈관신생 억제제 및 촉진제 시장 규모는 2024년부터 2031년까지 예측 기간 동안 연평균 10.01%의 CAGR로 성장하여 2023년 251억 5,000만 달러에서 2031년에는 539억 5,000만 달러 규모로 성장할 것으로 예상됩니다.
폐암, 유방암, 전립선암 등 다양한 종류의 암에 대한 부담이 증가함에 따라 치료법 개발에 대한 투자가 증가하고 있습니다. 미국암협회(American Cancer Society)에 따르면, 2023년 미국에서만 195만 8,310명의 신규 암 환자와 60만 9,820명의 암 관련 사망자가 발생할 것으로 보고되고 있습니다. 또한, 다양한 질환의 치료에서 혈관신생 억제제 및 촉진제 사용에 대한 인식이 높아지고 기술 발전도 시장 성장을 뒷받침하고 있습니다. 기술 발전은 혈관신생 억제제 및 촉진제 개발에 혁명을 일으키고 있습니다. 리포좀과 나노입자를 포함한 새로운 약물전달 시스템은 부작용을 줄이고 약효를 향상시키고 있습니다. 또한, 조직공학 기술과 생체재료의 통합은 혈관신생을 조절할 수 있는 새로운 수단의 개발을 지원하고 있습니다.
암 유병률의 증가는 시장 성장을 뒷받침
전 세계적으로 다양한 유형의 암의 유병률이 증가함에 따라 혈관신생 억제제에 대한 수요가 증가하고 있습니다. Johns Hopkins Medicine에서 발표한 논문에 따르면, 혈관신생 억제제인 베바시주맙은 전이성 신세포암, 대장암, 신경내분비 종양, 비소세포폐암, 신경교모세포종, 간암 등 다양한 종류의 암을 치료하는 데 도움이 되고 있습니다. 간암 등 다양한 종류의 암을 치료하는 데 도움이 되고 있습니다.
R&D 활동 중시
R&D 활동은 혁신 지원, 신규 제품 및 서비스 개발 촉진, 기존 제품의 효능 향상 등 다양한 이점이 있습니다. 이러한 활동은 표적 치료의 정확성과 효능을 향상시키고, 연구자들이 기존 제품의 한계를 줄일 수 있도록 돕습니다. 다케다제약(Takeda Pharmaceuticals)은 보르테조밉 기반 도입 요법을 받은 적이 있는 환자를 대상으로 덱사메타손과 덱사메타손의 병용요법을 개발하기 위해 R&D 활동을 활발히 진행하고 있습니다. 다발성 골수종 환자를 대상으로 덱사메타손과 레날리도미드(Lenalidomide)를 병용한 룩사조밉의 다발성 골수종 진행에 대한 2년간의 효과를 평가하기 위한 중재적 임상 4상 시험을 진행 중입니다. 이 시험은 덱사메타손과 레날리도마이드의 전 경구용 병용요법과 룩사조밉을 병용하는 참가자들의 안전성과 유효성을 검토하고 있습니다.
세계 혈관신생 억제제 및 촉진제 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이와 예측, 각종 분류 및 지역별 상세 분석, 산업 구조, 시장 성장에 영향을 미치는 요인 분석, 사례 연구, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
Global angiogenesis inhibitors and stimulators market is projected to witness a CAGR of 10.01% during the forecast period 2024-2031, growing from USD 25.15 billion in 2023 to USD 53.95 billion in 2031. The growing burden of different types of cancers, including lung, breast, and prostate cancer, is increasing investments in developing different therapeutic treatments. As per the American Cancer Society, in 2023, 1,958,310 new cancer cases and 609,820 cancer related deaths occurred in the United States alone. Furthermore, the growing awareness about the utilization of angiogenesis inhibitors and stimulators for the treatment of various conditions and technological advancements are supporting the market growth. Advancements in technology are revolutionizing the development of angiogenesis stimulators and inhibitors. Novel drug delivery systems, including liposomes and nanoparticles, reduce side effects and improve drug efficacy. Additionally, tissue engineering techniques and the integration of biomaterials are supporting the development of novel avenues for modulation of angiogenesis.
The growth of medical tourism in different regions across the globe is also expected to augment the growth of the market in the coming years. Such factors encourage different governments and research organizations to support novel product development and research activities. Key players and market and research institutions are heavily engaged in research and development activities to develop novel products that offer enhanced therapeutic efficacy. For instance, the National Cancer Institute of Naples are in the phase 4 of a study that is being conducted to explore the role of biological and clinical factors in patients with ovarian cancer who are receiving paclitaxel and carboplatin with bevacizumab.
Increasing Prevalence of Cancer Supports Market Growth
The growing prevalence of different types of cancer in various regions across the globe is propelling the requirement for angiogenesis inhibitors. These inhibitors prevent the growth of the tumor and stabilize it by blocking the formation of new blood vessels. According to an article published by Johns Hopkins Medicine, Bevacizumab, an angiogenesis inhibitor medicine, aids in the treatment of different types of cancer, including metastatic renal cell cancer, colorectal cancer, neuroendocrine tumors, non-small cell lung cancer, glioblastoma, and liver carcinoma.
Due to the central role of the VEGF/VEGFR signaling axis in cancer angiogenesis, various anti-angiogenic medicines, including VEGFR tyrosine kinase inhibitors (TKIs), anti-VEGF antibodies, and anti-VEGFR antibodies, have been authorized for different types of cancer. Researchers Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, et al. discovered that treatment with Bevacizumab and hypoxia-inducible factor 1(HIF-1) inhibitors have a greater anti-cancer impact as opposed to therapy with Bevacizumab only in glioma xenografts. Furthermore, various market players are also investing in evaluating the safety and efficacy of Bevacizumab, including Hoffmann-La Roche, which is conducting a stage four clinical trial in an interventional study of Bevacizumab in patients suffering from metastatic or advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Increasing Emphasis on Research and Development Activities
Research and development activities offer various benefits, including supporting innovation, facilitating the development of novel products and services, and enhancing the efficacy of existing products. These activities enhance the accuracy and efficacy of targeted therapies and allow researchers to reduce the existing limitations of the product. Various market players and research organizations are heavily engaged in research and development activities to promote the development of products that provide enhanced therapeutic efficacy and understand the effects of existing therapies in combination with others. For instance, Takeda Pharmaceuticals is in phase 4 of their interventional study that aims to evaluate the effect of lxazomib in combination with dexamethasone and lenalidomide on the progression of multiple myeloma in two years in patients who had previously received a bortezomib-based induction regimen. The study will look at the safety and effectiveness of participants who are taking the all-oral combination of dexamethasone and lenalidomide with lxazomib.
North America Dominates Angiogenesis Inhibitors and Stimulators Market
North America is expected to account for a significant share of the market owing to the strong presence of various leading market players and the rapid expansion of the biotechnology and pharmaceutical industry in the region. The large patient base and expansion of the treatment seeking population in North America are further bolstering the market growth.
Due to the increasing prevalence of various diseases, including diabetic retinopathy, metastasis, and tumor formulation, various research institutions and organizations are heavily investing in research activities for the development of novel therapies and enhancing their efficacy. For instance, the Greater Houston Retina Research is in the phase four of their interventional study of long-term efficacy and safety of intravitreal aflibercept injections for treating diabetic retinopathy for subjects who completed the 2-year PANORAMA trial. The subjects will be evaluated for efficacy with the aid of best corrected visual acuity by using spectral domain optical coherence tomography (SD-OCT), fluorescein angiography (FA), optical coherence tomography angiography (OCT-A), FP, 4-meter ETDRS protocol with normal-luminance, and Humphrey Visual Field (HVF) through 112 weeks.
In Vitro Angiogenesis Accounts for Significant Market Share
The in vitro application accounts for a significant share of the market owing to the increasing utilization of the device for the measurement of proteins among other substances available in tissues and biological fluids, such as serum, blood, and urine. For instance, the CHEMICON In Vitro Angiogenesis Kit provides a system for evaluating tube formation by endothelial cells in a 96-well format. This kit represents a simple model of angiogenesis where the inhibition or induction of tube formation by exogenous signals is monitored easily. The assay can be used for monitoring the extent of tube assembly in different endothelial cells such as bovine capillary endothelial cells and human umbilical vein cells.
Hospitals Expected to Witness Significant Growth Over Forecast Period
The hospital segment is expected to generate significant revenue due to the high demand for angiogenesis inhibitors and stimulators owing to increased awareness and rising incidences of patients with uncontrolled angiogenesis. The increased spending of hospitals on angiogenesis inhibitor and stimulator therapies can also be attributed to the growing requirement for innovative therapies due to the expansion of the medical tourism industry. The increasing prevalence of age-related macular degeneration is further encouraging hospitals to invest in angiogenesis inhibitors as they are critical for the treatment and prevention of the disease. According to an article published in Journal Cureus, in September 2022, it was estimated that 200 million people suffer from AMD. This number is projected to increase to roughly 300 million by 2040.
Future Market Scenario (2024 - 2031F)
Takeda Pharmaceuticals, one of the leading research and development driven pharmaceutical companies, is involved in an interventional study that aims to evaluate the effect of lxazomib in combination with dexamethasone and lenalidomide on the progression of multiple myeloma in two years in patients who had previously received a bortezomib-based induction regimen. The study is expected to conclude in November 2026.
The National Cancer Institute of Naples is in the phase 4 of a study that is being conducted to explore the role of biological and clinical factors in patients with ovarian cancer that are receiving paclitaxel and carboplatin with bevacizumab. The study is expected to conclude in December 2024.
Key Players Landscape and Outlook
Key participants in the angiogenesis inhibitors and stimulators market include F. Hoffmann-La Roche, Ltd., Bristol-Myers Squibb Company, Eyetech, Inc., Bayer AG, and Takeda Pharmaceutical Company Ltd. The market is witnessing significant growth owing to rising investments in healthcare infrastructure, advancements in precision medicine, and increasing prevalence of cancer.
Hoffmann-La Roche, a multinational healthcare and pharmaceutical company, is conducting a stage four clinical trial in an interventional study of Bevacizumab in patients suffering from metastatic or advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. The study is expected to conclude in June 2025.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work